Foundation Launches New Collaboration with AMRI
| 1 min read

Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, announced today a four-year research collaboration with the biotech firm AMRI, worth up to $23.7 million, aimed at identifying novel treatments that address the core defect in cystic fibrosis.

The agreement calls for AMRI to screen its natural products-based libraries to find compounds that improve the function of the defective protein in CF, known as the Cystic Fibrosis Transmembrane conductance Regulator (CFTR).

"With this collaboration, we are proving once again that we will explore every promising avenue to find new therapies for people with CF," said Robert J. Beall, Ph.D, president and CEO of the Cystic Fibrosis Foundation. "We are excited about the potential of AMRI's cutting-edge natural products capabilities to complement our existing small molecule drug discovery strategy."

Click here to read the full release.

Share this article
Topics
Research
Recent news
CF Foundation Awards $1.6 Million to Improve Detection of Lung Transplant Complication
News | 5 min read
CF Foundation Announces New National Advocacy Chairs
News | 5 min read
More Than 160 Advocates Raise Their Voices for PASTEUR Act During March on the Hill
News | 3 min read
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.

Subscribe